An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Phase: PHASE2
Conditions: Clostridium Difficile Infection
Sponsor: Rebiotix Inc.

Rebiotix Inc. 
Protocol 2015-01 
 An Open-label Efficacy and Safety Assessment of Rebiotix 
RBX2660 (microbiota suspension) for the Treatment of 
Recurrent Clostridium difficile Infection  
NCT02589847 
Version 5.0, Date 20 Jan 2016